[HTML][HTML] Chemotherapy for small cell lung cancer: a comprehensive review
SM Karim, J Zekri - Oncology reviews, 2012 - ncbi.nlm.nih.gov
Combination chemotherapy is the current strategy of choice for treatment of small cell lung
cancer (SCLC). Platinum containing combination regimens are superior to non-platinum …
cancer (SCLC). Platinum containing combination regimens are superior to non-platinum …
Current status of clinical trials for small cell lung cancer
A Arcaro, B Fischer - Reviews on recent clinical trials, 2008 - ingentaconnect.com
SCLC represents 13% of all lung cancer cases and is the most aggressive form of lung
cancer with an overall 5-year survival less than 5%. The combination of cisplatin or …
cancer with an overall 5-year survival less than 5%. The combination of cisplatin or …
[PDF][PDF] Мелкоклеточный рак легкого
МБ Бычков, ЭН Дгебуадзе… - Практическая …, 2005 - molneo.com
Эффективность современной терапии данной формы МРЛ колеблется от 65% до 90%,
с полной регрессией опу холи у 45–75% больных и медианой выживаемости 18–24 мес …
с полной регрессией опу холи у 45–75% больных и медианой выживаемости 18–24 мес …
Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
CS Baldotto, EH Cronemberger, P de Biasi… - Supportive Care in …, 2012 - Springer
Purpose Small cell lung cancer (SCLC) is an aggressive malignancy but with a high
response rate to chemotherapy. Eastern Cooperative Oncology Group performance status …
response rate to chemotherapy. Eastern Cooperative Oncology Group performance status …
Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group …
M Neubauer, J Schwartz, J Caracandas… - Journal of clinical …, 2004 - ascopubs.org
Purpose To determine the 1-year survival, response rate (RR), time to progression (TTP),
and safety of weekly paclitaxel plus carboplatin (PC) in patients with extensive small-cell …
and safety of weekly paclitaxel plus carboplatin (PC) in patients with extensive small-cell …
Chemotherapy strategies in the treatment of small cell lung cancer
S Popat, M O'Brien - Anti-cancer drugs, 2005 - journals.lww.com
Lung cancer is the most prevalent, yet most preventable malignancy worldwide. Given the
tendency of small cell lung cancer (SCLC) to early relapse and its subsequent resistance to …
tendency of small cell lung cancer (SCLC) to early relapse and its subsequent resistance to …
Significant activity of single agent vinorelbine against small-cell cancer of the bladder as second line chemotherapy: a case series and review of the literature
RR June, DW Dougherty, CT Reese… - … Oncology: Seminars and …, 2012 - Elsevier
Small-cell carcinoma of the urinary bladder is an extremely uncommon form of urologic
malignancy, accounting for less that 1% of new cases of bladder cancer. It is an aggressive …
malignancy, accounting for less that 1% of new cases of bladder cancer. It is an aggressive …
[引用][C] Influence of FasL gene expression on hepatic
SY Li, B Yu, P An, JC Wei, FY Zuo, HY Cai - Hepatobiliary Pancreat Dis Int